One Million Syringes of RADIESSE(r) Dermal Filler Have Been Shipped

RADIESSE Dermal Filler Has Become One of the Leading Dermal Fillers Worldwide

SAN MATEO, Calif. and PARIS, (GlobeNewswire via COMTEX News Network) — BioForm Medical, Inc. (Nasdaq:BFRM) today announced, at a presentation at the 11th Annual Meeting of the International Master Course on Aging Skin (IMCAS), that it has shipped more than 1,000,000 syringes of RADIESSE(r) dermal filler worldwide since 2002. RADIESSE dermal filler has been available since 2002 for aesthetic uses in the Europe and for reconstructive and therapeutic uses in the United States. In 2006, BioForm Medical received U.S. Food and Drug Administration approval of RADIESSE dermal filler for facial aesthetics applications, and use of this product has rapidly expanded. RADIESSE dermal filler has demonstrated an excellent safety profile, comparable to short term hyaluronic acid products. RADIESSE dermal filler is also the only dermal filler to have demonstrated, in peer-reviewed studies, better aesthetic correction and higher patient satisfaction than Restylane(r) and Juvederm(r).

As of December 2008, BioForm Medical has supplied more than 1,000,000 syringes of RADIESSE dermal filler to approximately 10,000 medical and aesthetics practices worldwide. With the rapid adoption of this product, RADIESSE dermal filler has become one of the leading dermal fillers in the worldwide market. BioForm Medical believes that to date, RADIESSE dermal filler is the only dermal filler, other than collagen and hyaluronic acid, to reach this 1,000,000 syringe milestone.

Industry-Leading Peer Reviewed Publications with RADIESSE Dermal Filler

More than 60 published peer-reviewed scientific articles have demonstrated the utility of RADIESSE dermal filler. The studies and clinical publications collectively reporting on several-thousand-patient experience with RADIESSE dermal filler include:

* 117-patient comparative study vs. Cosmoplast (human collagen) by Dr.
Stacy Smith, Dr. Mariano Busso, Dr. Marla McClaren and Dr. Lawrence
Bass published in the Journal of Dermatologic Surgery in December
2007, which supported FDA approval for fold and wrinkle treatment,
showed superior performance of RADIESSE dermal filler vs.
Cosmoplast on nearly every measure evaluated

* 60-patient split-face, blinded comparative study vs. Restylane by
Dr. Marion Moers-Carpi and Dr. Jaime Tufet published in the Journal
of Dermatologic Surgery in February 2008, which demonstrated more
patients improved at 6 months and 9 months following treatment with
RADIESSE dermal filler than with Restylane, and higher patient
satisfaction with RADIESSE dermal filler than with Restylane

* 205-patient randomized, blinded comparative study vs. Juvederm and
Perlane by Dr. Marion Moers-Carpi, Dr. Stephan Vogt, Dr. Begonia
Santos, Dr. Jorge Planas, Dr. Sonia Vallve and David Howell, PhD
published in the Journal of Dermatologic Surgery in December 2007,
which demonstrated higher patient satisfaction and greater
likelihood of patients to return if treated with RADIESSE dermal
filler compared with Juvederm or Perlane

* 100-patient study treating patients with HIV-associated lipoatrophy
by Dr. Stacey Silvers, Dr. Joseph Eviatar, Dr. Michael Echavez and
Dr. Alexandra Pappas that demonstrated safety of treatment with up
to 15 syringes of RADIESSE dermal filler, which was published in
the Plastic and Reconstructive Surgery Journal in September 2006

* 1,000-patient clinical report of 4-year follow-up with RADIESSE
dermal filler by Dr. Thomas Tzikas published in the Journal of
Dermatologic Surgery in June 2008

* 58-patient radiographic and computed tomographic imaging study of
RADIESSE dermal filler in nasolabial fold and HIV-associated
lipoatrophy treatment by Dr. Alastair Carruthers, Dr. Jean
Carruthers, Dr. Marc Liebeskind and Dr. Bruce Forster published in
the Journal of Dermatologic Surgery in June 2008

* 24-patient, 26-month clinical report on nasal augmentation with
RADIESSE dermal filler by Dr. Hilton Becker published in the
Plastic and Reconstructive Surgery Journal in June 2008

* 5-patient clinical report to characterize new collagen formation
following RADIESSE dermal filler treatment by Dr. Alexander Berlin,
Dr. Mussarratt Hussain and Dr. David Goldberg published in the
Journal of Dermatologic Surgery in June 2008

* An investigation of physical properties when RADIESSE dermal filler
is mixed with lidocaine by Dr. Mariano Busso published in the
Journal of Dermatologic Surgery in June 2008

* 19-patient clinical report on the use of RADIESSE dermal filler for
mid-face volume loss by Dr. Kenneth Beer, Monica Yohn, RN and Dr.
Joel Cohen published in the Journal of Drugs in Dermatology in
April 2008

* 14-patient clinical report on nonsurgical rhinoplasty with RADIESSE
dermal filler by Dr. Cameron Rokhsar and Dr. David Ciocon published
in the Journal of Dermatologic Surgery in April 2008

* 113-patient clinical report on patient satisfaction outcomes with
RADIESSE dermal filler from three physicians’ practices by Dr. Neil
Sadick, Dr. Bruce Katz and Dr. Deborshi Roy published in the
Journal of Dermatologic Surgery in December 2007

* A clinical report on the use of RADIESSE dermal filler in hand
augmentation by Dr. Mariano Busso and Dr. David Applebaum published
in the Journal of Dermatologic Therapy in November 2007

* 13-patient clinical report on the use of RADIESSE dermal filler for
the correction of post-rhinoplasty contour deficiencies by Dr.
Howard Stupak, Dr. Thomas Moulthrop, Patricia Wheatley, RN,
Allison Tauman, PharmD, and Dr. Calvin Johnson published in the
Archives of Facial Plastic Surgery in March 2007

* 22-patient, 12-18 month clinical report on the use of RADIESSE
dermal filler for the correction of nasolabial fold depressions by
Dr. Murad Alam and Dr. Simon Yoo published in the Journal of the
American Academy of Dermatology in February 2007

* 139-patient clinical report on the use of RADIESSE dermal filler in
multiple aesthetic indications by Dr. Silvia Cuevas, Dr. Maria
Patricia Rivas, Dr. Sadegh Amini and Dr. Eduardo Weiss published in
the American Journal of Cosmetic Surgery in October 2006

* 609-patient clinical report on the use of RADIESSE dermal filler in
multiple aesthetic indications by Dr. David Jansen and Dr. Miles
Graivier published in the Plastic and Reconstructive Surgery
Journal in September 2006

* 40-patient, 18-month clinical report on the use of RADIESSE dermal
filler by Dr. Patricio Jacovella, Dr. Claudia Peiretti, Dr. Diego
Cunille, Dr. Mauricio Salzamendi and Dr. Sophia Asiu Schechtel
published in the Plastic and Reconstructive Surgery Journal in
September 2006

About RADIESSE Dermal Filler
RADIESSE dermal filler is approved in the United States for the correction of moderate to severe facial folds and wrinkles, including nasolabial folds and for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with HIV. In Europe, RADIESSE dermal filler is CE-marked for plastic and reconstructive surgery, including deep and sub-dermal soft tissue augmentation of the facial area. We believe that the general advantages of RADIESSE dermal filler that have enabled the rapid uptake of the product include: excellent initial correction, durability of treatment of one year or longer in many patients, and the physical characteristics of holding shape and lifting tissues better than some filler materials. Procedural side effects from RADIESSE dermal filler injection are consistent with side effects commonly associated with injectable dermal filler treatments, and may include bruising, swelling, redness, pain, and itching. In most cases, these side effects go away within two weeks following treatment. There have been no reported long term adverse effects of RADIESSE dermal filler in the pivotal clinical studies conducted, and there have been no reports of delayed onset adverse events in these clinical studies.

About BioForm Medical, Inc.
BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California, developing products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm Medical’s lead product is RADIESSE(r) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. For more information about BioForm Medical, please visit www.bioform.com.

RADIESSE(r) is a registered trademark of BioForm Medical, Inc. Restylane(r) is a registered trademark of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical Corporation.

Juvederm(r) mark owned by Allergan Industrie SAS.

BioForm Medical, Inc.
866.862.1211
www.radiesse.com

Source: BioForm

Cutera’s Pearl Fractional Laser Receives Health Canada Clearance

95% of patients surveyed would recommend a Pearl Fractional treatment

BRISBANE, Calif., January 27, 2009 — Cutera, Inc.® (Nasdaq: CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, today announced Health Canada approval for its Pearl Fractional laser for skin resurfacing and the treatment of wrinkles.

“Pearl Fractional shipments are commencing immediately into the Canadian market,” Cutera President and CEO Kevin Connors said. “This approval confirms that Pearl Fractional meets all health, safety, and environmental standards required by Canada’s Ministry of Health.”

“Pearl Fractional is designed to safely and effectively repair deep dermal imperfections in just one treatment with an average recovery of five days,” Connors continued. “And our customers’ outstanding clinical results and histology data support that it’s working. A recent study revealed that 94 percent of patients were pleased to extremely happy with their treatment results and 95 percent of patients would recommend a Pearl Fractional treatment.”

“Pearl Fractional can be used on the entire face or just problem areas. It is especially good for treating the periorbital, perioral and jawline areas,” said Brian Biesman, M.D., medical director of the Nashville Centre for Laser and Facial Surgery in Nashville, TN and current president of the American Society for Laser Medicine and Surgery.

Biesman continued, “When combined with Cutera’s Pearl laser for full epidermal renewal, I have a unique solution for a deep and full coverage treatment. My patients are thrilled to see improvements in not only their wrinkles, but also with their uneven skin texture, pigmentation and sun damage. Pearl and Pearl Fractional offer a unique and outstanding option for skin rejuvenation.”

Pearl Fractional is the only fractional ablative laser based on the 2790 nm wavelength with proprietary YSGG technology. Due to its specific water absorption characteristics, 2790 nm is an optimal laser wavelength for providing the dual benefit of deep dermal ablation with a controlled zone of thermal coagulation to maximize results while minimizing post-operative downtime. Pearl Fractional received FDA clearance and CE Mark approval in 2008.

About Cutera, Inc.
Brisbane, Calif.-based Cutera is a leading provider of laser and other light-based aesthetic systems to the professional aesthetic market. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients.

Cutera, Inc.
888.4CUTERA (428-8372)
www.cutera.com

Source: Cutera

Palomar and Q-MED AB Terminate International Distribution Agreement

BURLINGTON, Mass., Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ — Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, today announced the termination of its international distribution agreement with the Swedish company Q-MED AB (OMX Nordic Exchange, Stockholm Mid Cap:QMED), a leading biotech/medical device company based in Uppsala, Sweden. The international distribution agreement was originally entered into in January 2008 with the intention that Q-MED would eventually be responsible for the marketing, advertising, promotion, sale and distribution of Palomar’s professional products for aesthetic treatments outside North America.

Due to the downturn in the world-wide economic environment, Q-MED’s efforts are being concentrated on their own product line of dermal fillers. Both Palomar and Q-MED agreed that Palomar will be better served by separately continuing to expand its existing distribution channel.

Joseph P. Caruso, Palomar Chief Executive Officer said, “Although we are choosing to end our distribution agreement, this was a good learning experience and we have forged a positive relationship with Q-MED that may be beneficial in the future. We believe that during these challenging economic times we will be better positioned with full control of our international distribution. We have signed up many new distributors over the past twelve months and continue to work closely with all of our distributors to help maximize their sales efforts. Territories outside North America should continue to provide growth opportunities for us as we expand our efforts.”

Bengt Agerup, Q-MED Chief Executive Officer said, “By working closely with Palomar we have learned more about Palomar’s top-end technological platforms and products. Considering the present challenging market conditions, Q-Med is focusing on its leading dermal filler product line, Restylane(R) as well as on the on-going launch of Macrolane(TM), the first injectable body contouring product line, and the Restylane Vital(TM) product line for skin rejuvenation. Hopefully we will be able to utilize our relationship and the knowledge we have built in the future. ”

About Palomar Medical Technologies, Inc.
Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

About Q-MED AB
Q-MED AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company’s patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane(R) for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux(TM) for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, Zuidex(TM) for the treatment of stress urinary incontinence in women, and Solesta(TM) for the treatment of fecal incontinence. Sales are made through the company’s own subsidiaries or distributors in over 70 countries. QMED today has just over 700 coworkers, with close to 500 at the company’s head office and production facility in Uppsala, Sweden. Q-MED AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

For more information on Q-MED and its products, visit Q-MED’s website at www.q-med.com. To continue receiving the most up-to-date information and latest news on Q-MED as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations section of the website.

Palomar Medical Technologies, Inc.
800.PALOMAR (725-6627)
www.palomarmedical.com

Source: Palomar

Elemé Medical Launches SmoothLipo™ Body Shaping Treatment

New Breakthrough Technology Leaves Skin Consistently Smooth and Visibly Tight

MERRIMACK, N.H. - Body-sculpting technology with consistently smooth and visibly tight results called SmoothLipo™ has launched in the U.S. and is now available to those who want effective body reshaping without major surgery. Launched by Elemé Medical Inc., a leader in aesthetic body shaping technology, SmoothLipo is a laser device for minimally invasive laser-assisted lipolysis, which contours the body by treating local fat deposits and is recommended for areas where skin laxity is a concern and the patient desires firmer and smoother-looking skin.

“The SmoothLipo device is a significant advance in the field of body contouring as it helps patients achieve localized fat reduction as well as optimum skin tightening,” said Dr. Cheryl Karcher, Manhattan-based, board-certified dermatologist who is an expert in fat reduction techniques and technologies. “I also like the decreased patient risk profile of the treatment compared to earlier laser lipolysis options. This laser is continuous wave which means there is less chance of the patient experiencing thermal injuries.”

The SmoothLipo device uses an advanced form of laser lipolysis, which better utilizes thermal energy to break down fat cells and tighten skin in the treated areas as demonstrated by three years of clinical and research experience. The breakthrough science includes the use of a 980-nm continuous wave laser, which creates greater body-shaping uniformity while allowing for a gentler effect on surrounding skin tissue, resulting in faster recovery time and less risk of patient complications.

“Plastic surgeons have been getting excellent results with traditional liposuction for more than three decades. I’ve investigated a number of techniques and technologies that showed minimal if any improvements over traditional liposuction techniques. In SmoothLipo studies, and in my experience with the device, it appears to stimulate skin tightening thereby adding to the benefits patients can get from a laser lipolysis procedure. Patients who may have required more extensive surgical lifts with skin laxity can have this much less extensive procedure and see more benefits than liposuction alone,” said Dr. Miles Graivier, Atlanta-based board certified plastic surgeon and body shaping expert.

During SmoothLipo, laser energy is delivered under the skin to the treatment area where it is transformed into heat. The heat creates higher temperatures in the fat cells, which results in their irreversible breakdown. The elevated temperature also shrinks collagen fibrils and stimulates new collagen production in the surrounding tissue, causing the appearance of tighter and smoother-looking skin. Both processes continue for several months following SmoothLipo treatment. The procedure is fast and any area of the body can be treated, including the neck, arms, knees, abdomen, thighs and hips.

About Elemé Medical
Elemé Medical, headquartered in Merrimack, N.H., is dedicated to providing market leading technology in all areas of body shaping. SmoothLipo™ is a medical device with FDA clearance to market. SmoothShapes® System with pioneering Photomology® technology is a medical device with FDA clearance and CE Mark approval to market.

Elemé Medical
877.333.5306
www.smoothshapes.com

Source: Elemé Medical

Preventing Wrist Pain with Innovative Fitness Glove

LOS ANGELES (January 15, 2008)—Paula Wilbert, founder of Joint Protection Products, LLC (JPP) and inventor of Wrist Assured™ Gloves (WAGs), introduces a special limited Valentine’s Day Edition of the innovative fitness glove. The concept consists of a pair of WAGs packaged in an eco-friendly and re-usable WAGs Bag, a pewter handcrafted charm featuring an open heart, and a charitable contribution. In the spirit of St. Valentine, $5.00 from the sale of each pair of limited edition WAGs goes to CARE (www.care.org)—a leading humanitarian organization fighting global poverty, especially for impoverished women. Valentine’s Day edition WAGs are available at www.GetWAGs.com for $59.95—a $10.00 discount off the regular price—while supplies last.

Wilbert says, “Instead of chocolates, support your sweetheart’s 2009 fitness resolutions and give the gift of workouts that are free of wrist pain.”

She adds, “WAGs are the perfect gift to show you care for the well-being of your Pilates or yoga loving partner, parent or friend. With improved comfort and alleviated wrist strain, loved ones will reap the mind-body benefits of a consistent exercise routine.”
The patent pending WAGs feature an ergonomically designed gel pad that is thicker at the heel of the hand, slightly decreasing the angle of wrist extension. The soft tissues of the wrist, including the ligaments and tendons, are subject to strain during weight bearing exercises on the hands.

A new version of WAGs will be introduced Spring 2009, which features a wrist wrap for even more support.

About JPP & WAGs
Paula Wilbert founded Joint Protection Products, LLC (JPP) in 2005 to house her patent pending fitness product, Wrist Assured™ Gloves (WAGs)—a revolutionary pain-relieving concept that is taking the fitness industry by storm. Since introducing the glove at the 2007 Yoga Journal Conference in San Francisco, the product’s popularity has spread throughout the globe. WAGs are made in the USA and Canada; a choice to be sweatshop free, support fair labor wages and reduce fuel consumption. JPP continues to create and develop innovative products that promote an active and pain-free lifestyle for overall well-being, while staying in alignment with socially conscious and eco-friendly principles.

Joint Protection Products, LLC
800.606.4JPP (4577)
www.GetWAGs.com

Source: WAGS

LuxarCare Assumes Lumenis’ Service Commitments to Luxar Customers

Lumenis® Ltd., of Yokneam, Israel has announced that their Luxar, AccuVet, and NovaPulse customers in the United States and Canada with maintenance or service inquiries will be directed to LuxarCare of Woodinville, Washington. The parties have concluded an agreement whereby LuxarCare will assume Lumenis’ service commitments to customers with warranty rights or service contracts for their Luxar laser products.

All customer maintenance and service inquiries or questions should be directed to Ms. Lynnette Hill, LuxarCare’s Customer Service Manager, or Dr. Peter Vitruk, General Manager. Customers may also direct their questions about this transfer of servicing activities to Lumenis.

LuxarCare
866.589.2722
www.luxarcare.com

Source: LuxarCare